Adenoid cystic carcinoma (AdCC) is a rare cancer originating from secretory glands with unknown aetiology. It one of the most dominant malignant salivary tumours (MST). However, it can arise in other areas head and neck region outside this area. occurs at all ages, but more frequent between 50-70 years age common females than males. The symptoms AdCC are generally unspecific clinical diagnosis maybe challenging, partially due to its heterogenous histopathology indolent growth. Moreover,...

Abstract The incidences of human papillomavirus‐positive (HPV + ) tonsillar and base tongue squamous cell carcinomas (TSCC BOTSCC) have increased in recent decades. Notably, HPV TSCC BOTSCC a significantly better prognosis than their HPV‐negative counterparts when treated with current surgical options, radiotherapy, or intensified chemoradiotherapy. However, cure is not achieved 20% patients TSCC/BOTSCC. Meanwhile, cured often present severe chronic side effects. This necessitates novel...

Long-term survival data in relation to sub-sites, human papillomavirus (HPV), and p16INK4a (p16) for patients with oropharyngeal squamous cell carcinoma (OPSCC) is still sparse. Furthermore, reports have indicated atypical late recurrences HPV p16 positive OPSCC. Therefore, we assessed long-term recurrence subsite HPV/p16 status. A total of 529 OPSCC, diagnosed the period 2000–2010, known HPVDNA p16-status, were included. status sub-sites correlated disease-free overall (DFS OS...

Human papillomavirus positive (HPV+) tonsillar and base of tongue squamous cell carcinoma (TSCC/BOTSCC), the major subsites oropharyngeal (OPSCC) have favorable outcome, but upon relapse, outcome is poor new therapies needed. Since, phosphatidyl-inositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) fibroblast-growth-factor-receptor-3 (FGFR3) mutations often occur in such tumors, here, we tested targeted therapy directed to genes TSCC/BOTSCC lines. We also combined two types...

Adenoid cystic carcinoma (AdCC), a rare heterogenous disease, presents diagnostic, prognostic, and therapeutic challenges. To obtain more knowledge, we conducted retrospective study on cohort of 155 patients diagnosed in 2000-2022 with AdCC the head neck Stockholm investigated several clinical parameters correlation to treatment prognosis 142/155 treated curative intent. The strongest favourable prognostic factors were early disease stage (stage I II) as compared late III IV) major salivary...

Abstract Purpose: Human papillomavirus (HPV) is the cause of majority cervical cancer cases and has been showed to be released as cell-free tumor DNA (ctHPV DNA) into circulation. Here, we analyze if ctHPV could used a prognostic biomarker and/or detect relapse earlier than traditional methods in locally advanced (LACC). Experimental Design: A total 74 patients with LACC were included; 66of positive for 13 high-risk HPV types on bead-based assay biopsy samples. HPV-type–specific droplet...

TNM-8 staging separates oropharyngeal squamous cell carcinomas (OPSCC) into human papillomavirus (HPV)-mediated and -unrelated OPSCC based on p16INK4a overexpression (p16+), as surrogate marker for HPV. However, is histologically clinically heterogenous including tonsillar base of tongue (TSCC BOTSCC respectively), soft palate walls (otherOPSCC). The significance HPV established in TSCC/BOTSCC, while its role otherOPSCC unclear, which not considered TNM-8. Here, p16+ was therefore evaluated...

Hypopharyngeal squamous cell carcinoma (HPSCC) has a very poor prognosis. Local surgery may increase survival, but is often avoided due to significant post-op co-morbidities. Since prognostic markers are lacking, the aim was find predictive biomarkers that identify patients whose response oncological treatment and who benefit from primary survival. Pretreatment biopsies 23 HPSCC patients, 3 human papillomavirus (HPV) positive 20 HPV-negative, were analyzed for expression of 750 mRNAs using...

Background Oropharyngeal squamous cell carcinoma (OPSCC) is dominated by tonsillar and tongue base carcinomas (TSCC/BOTSCC), but there are at other sites, such as uvula/soft palate/pharyngeal wall here defined OPSCC. Human papillomavirus (HPV) positive TSCC/BOTSCC have favorable outcome, the TNM-classification separates OPSCC into HPV mediated (p16INK4a overexpressing, p16+) unrelated non-overexpressing, p16-) cancer, prognostic role of p16+ in unclear.Aims/Objectives This study therefore...

An aetiological role of human papillomavirus (HPV) and/or polyomaviruses (HPyVs) has been proposed in adenoid cystic carcinoma (AdCC). Moreover, HPV-related multiphenotypic (HMSC) was recently introduced as an emerging entity the sinonasal region. Here, we primarily want to study HPV/HPyV a large AdCC cohort and, secondly, possibly identify and characterize HMSC. Tumour DNA from 68 patients initially diagnosed with between 2000 2012 was, therefore, tested for 27 HPV types 10 HPyVs....

Human papillomavirus positive (HPV+) tonsillar and base of tongue squamous cell carcinoma (TSCC/BOTSCC) have a favorable outcome, but upon relapse, survival is poor new therapeutical options are needed. Recently, we found synergistic effects by combining the food drug administration approved (FDA) phosphoinositide 3-kinase (PI3K) fibroblast-growth-factor-receptor (FGFR) inhibitors BYL719 JNJ-42756493 on TSCC lines. Here this approach was extended Cyclin-Dependent-Kinase-4/6 (CDK4/6)...

Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is associated with a favourable prognosis. It has therefore been suggested that treatment should be individualized and separated by HPV status. However, additional prognostic markers are still needed before can for this patient group. For purpose, all patients diagnosed p16-positive OPSCC in Stockholm 2000-2009, identified as having partial/nonresponse to viable tumour cells their neck specimen material...

Patients with human papillomavirus DNA positive (HPVDNA+) and p16ink4a overexpressing (p16+) oropharyngeal squamous cell carcinoma (OPSCC), especially those cancer in the tonsillar base of tongue subsites as compared to other OPSCC have a better outcome than only HPVDNA+ or p16+ cancer. Likewise having high viral load has been suggested be prognostic factor. We therefore hypothesized, that HPV could vary depending on subsite, well regard whether was p16+, HPVDNA+, this affected outcome. To...

Background/Aim: Human papillomavirus positive (HPV⁺) oropharyngeal squamous cell carcinoma (OPSCC) is rising in incidence. Compared to HPV-negative (HPV^–) OPSCC, HPV⁺ cases have a better 5-year survival. With its severe side-effects, today's chemoradiotherapy has not improved outcome compared radiotherapy alone, so new therapies are needed. Mutations phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), fibroblast growth factor...

<div>Abstract<p><b>Purpose</b>: Human papillomavirus (HPV) is the cause of majority cervical cancer cases and has been showed to be released as cell-free tumor DNA (ctHPV DNA) into circulation. Here, we analyze if ctHPV could used a prognostic biomarker and/or detect relapse earlier than traditional methods in locally advanced (LACC).</p><p><b>Experimental Design</b>: A total 74 patients with LACC were included; 66of positive for 13 high-risk...

Human papillomavirus positive (HPV+) tonsillar and base of tongue cancer (TSCC/BOTSCC) is rising in incidence, but chemoradiotherapy not curative for all. Therefore, targeted therapy with PI3K (BYL719), PARP (BMN-673), WEE1 (MK-1775) inhibitors alone or combined was pursued without 10 Gy their effects were analyzed by viability, proliferation, cytotoxicity assays on the TSCC/BOTSCC cell lines HPV+ UPCI-SCC-154 HPV− UT-SCC-60A. Effective single drug/10 combinations validated additional TSCC...

Chemotherapy-related encephalopathy is a rare but severe side effect of cancer therapy. Few reports exist on the course due to 5-fluorouracil (5FU)/carboplatin treatment. Here, we report patient in his 70s, who received first-line palliative treatment with carboplatin followed by continuous infusion 5FU against metastasized base tongue. During first infusion, developed coma sudden onset. In contrast earlier 5FU-induced encephalopathy, serum ammonium levels were near-normal, despite slightly...

<p>Supplementary results and discussion on normal cfDNA.</p>

<p>Supplementary Figure S7. Number of copies ctHPV DNA at different timepoints for all patients (n = 13) who experienced disease progression early follow-up or tumor evaluation shortly thereafter and thus were not deemed to have had complete response treatment.</p>

<p>Supplementary Figure S4. Kaplan–Meier graphs of comparisons between patients with ctHPV DNA–positive (dotted, bottom lines) and DNA–negative (solid, top plasma at early-follow up/tumor evaluation (1-4 month after finished treatment) plasma.</p>

<p>Supplementary Figure S4. Kaplan–Meier graphs of comparisons between patients with ctHPV DNA–positive (dotted, bottom lines) and DNA–negative (solid, top plasma at early-follow up/tumor evaluation (1-4 month after finished treatment) plasma.</p>

<p>Supplementary Figure S5. Progression-free survival according to complete clinical response or not, at tumor evaluation, approximately 3 months after finished treatment.</p>